In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Investors Like “Breakthrough” Therapies, But Real Test Still To Come

Executive Summary

FDA confidence to devote time and resources for a breakthrough product resonates with investors and analysts, but the real program value in terms of product sales is yet to be seen. Sponsors also must be careful to manage investor expectations once the breakthrough designation is secured.

Advertisement

Related Content

Breakthrough In Two Pages: FDA Offers Preliminary Advice
PDUFA Negotiations: Early Communications, Breakthrough Still On Docket
PDUFA VI: Breakthrough Issues Among FDA Priorities
Breakthrough Requests: FDA Adds Quick Screen To Pare Workload
Beyond "Breakthrough": FDA, Industry See Benefits For Drugs Outside Expedited Pathway
Vertex’s Latest Bid For Kalydeco Label Expansion Heads To FDA Panel
“Breakthrough” Flexibility: FDA Answers Industry Call On Manufacturing Data
What’s Breakthrough Status Worth? Analysts Ask, But Companies Don’t Have Answers
Breakthrough Therapies: FDA Not Writing A Scientific Guidance – Yet

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV004160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel